{"transactions":[{"id":728764,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:35:15.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001221355-26-000002","document":"wk-form4_1782246909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135526000002/wk-form4_1782246909.xml","form_type":"4"}},{"id":728763,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:35:15.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":47700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":47700},"source":{"system":"sec-edgar","filing":"0001221355-26-000002","document":"wk-form4_1782246909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135526000002/wk-form4_1782246909.xml","form_type":"4"}},{"id":728762,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T20:35:15.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":47700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":398463,"source":{"system":"sec-edgar","filing":"0001221355-26-000002","document":"wk-form4_1782246909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135526000002/wk-form4_1782246909.xml","form_type":"4"}},{"id":960801,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-12-22T23:57:11.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":false,"shares":47700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2025, this grant was erroneously reported as 94,500 shares and is corrected here upon the vesting of the first of the semi-annual installments."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":47700,"derivative":{"underlying":"Common Stock","underlying_shares":47700},"source":{"system":"sec-edgar","filing":"0001221355-25-000005","document":"wk-form4_1766447828.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135525000005/wk-form4_1766447828.xml","form_type":"4"}},{"id":960800,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-22T23:57:11.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":true,"shares":47700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":350763,"source":{"system":"sec-edgar","filing":"0001221355-25-000005","document":"wk-form4_1766447828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135525000005/wk-form4_1766447828.xml","form_type":"4"}},{"id":1103579,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-24T01:03:01.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":94500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":94500,"derivative":{"underlying":"Common Stock","underlying_shares":94500},"source":{"system":"sec-edgar","filing":"0001737287-25-000071","document":"wk-form4_1750726975.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000173728725000071/wk-form4_1750726975.xml","form_type":"4"}},{"id":1104827,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:17.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017827","document":"form4-06202025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000141588925017827/form4-06202025_040612.xml","form_type":"4"}},{"id":1104826,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:17.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017827","document":"form4-06202025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000141588925017827/form4-06202025_040612.xml","form_type":"4"}},{"id":1104825,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:17.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":3.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017827","document":"form4-06202025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000141588925017827/form4-06202025_040612.xml","form_type":"4"}},{"id":1104824,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:15:17.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":24.18,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":20600},"source":{"system":"sec-edgar","filing":"0001415889-25-017827","document":"form4-06202025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000141588925017827/form4-06202025_040612.xml","form_type":"4"}},{"id":1104823,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:15:17.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":94481,"price":0.57,"value":53854.17,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"68,815 of the shares are held jointly with spouse."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-017827","document":"form4-06202025_040612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000141588925017827/form4-06202025_040612.xml","form_type":"4"}},{"id":1468657,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-26T20:32:40.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-24-018232","document":"form4-06262024_080637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000141588924018232/form4-06262024_080637.xml","form_type":"4"}},{"id":1486414,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-07T21:28:42.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":191082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":191082,"derivative":{"exercise_price":2.44,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":191082},"source":{"system":"sec-edgar","filing":"0001593968-24-000836","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000159396824000836/primary_01.xml","form_type":"4"}},{"id":1844088,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T20:09:59.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-23-039687","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919123039687/doc4.xml","form_type":"4"}},{"id":1854083,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T20:56:05.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":116120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":116120,"derivative":{"exercise_price":5.7,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":116120},"source":{"system":"sec-edgar","filing":"0001593968-23-001007","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000159396823001007/primary_01.xml","form_type":"4"}},{"id":2219284,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T20:08:56.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":3.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-22-039778","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919122039778/doc4.xml","form_type":"4"}},{"id":2227287,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-17T20:58:30.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":44178,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":303063,"source":{"system":"sec-edgar","filing":"0001214659-22-008170","document":"marketforms-56492.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465922008170/marketforms-56492.xml","form_type":"4"}},{"id":2341455,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T23:26:24.000Z","date":"2022-03-07","kind":"gift","acquired":false,"shares":412618,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The transactions reported in this form did not involve a purchase or sale of securities by the reporting person.  On March 7, 2022, the reporting person acquired securities previously held in trust for the benefit of the reporting person arising from the termination of the trust. On the same day, the reporting person transferred the same securities to an irrevocable grantor trust having an independent trustee. The reporting person disclaims beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein."}],"balance_after":258885,"source":{"system":"sec-edgar","filing":"0001214659-22-003836","document":"marketforms-55743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465922003836/marketforms-55743.xml","form_type":"4"}},{"id":2341454,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T23:26:24.000Z","date":"2022-03-07","kind":"other","acquired":true,"shares":412618,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The transactions reported in this form did not involve a purchase or sale of securities by the reporting person.  On March 7, 2022, the reporting person acquired securities previously held in trust for the benefit of the reporting person arising from the termination of the trust. On the same day, the reporting person transferred the same securities to an irrevocable grantor trust having an independent trustee. The reporting person disclaims beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein."}],"balance_after":671503,"source":{"system":"sec-edgar","filing":"0001214659-22-003836","document":"marketforms-55743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465922003836/marketforms-55743.xml","form_type":"4"}},{"id":2341451,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T21:40:59.000Z","date":"2022-03-07","kind":"gift","acquired":false,"shares":211000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On March 7, 2022, the reporting person transferred 211,000 shares of common stock to an irrevocable grantor trust having an independent trustee. The reporting person disclaims beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"68,815 of the shares are held jointly with spouse."}],"balance_after":94481,"source":{"system":"sec-edgar","filing":"0001209191-22-017600","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919122017600/doc4.xml","form_type":"4"}},{"id":2341450,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T21:40:59.000Z","date":"2022-03-07","kind":"gift","acquired":true,"shares":211000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"68,815 of the shares are held jointly with spouse."}],"balance_after":305481,"source":{"system":"sec-edgar","filing":"0001209191-22-017600","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919122017600/doc4.xml","form_type":"4"}},{"id":2434716,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T19:13:32.000Z","date":"2022-01-12","kind":"purchase","acquired":true,"shares":15000,"price":12.6,"value":189000.0,"ownership":{"direct":true},"balance_after":258885,"source":{"system":"sec-edgar","filing":"0001214659-22-000706","document":"marketforms-55053.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465922000706/marketforms-55053.xml","form_type":"4"}},{"id":2656932,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-24T01:16:11.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":20600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":20600,"derivative":{"exercise_price":24.18,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":20600},"source":{"system":"sec-edgar","filing":"0001209191-21-042884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919121042884/doc4.xml","form_type":"4"}},{"id":2671594,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-11T21:43:06.000Z","date":"2021-06-11","kind":"gift","acquired":false,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On June 11, 2021, the reporting person transferred 500,000 shares of common stock to an irrevocable grantor trust having an independent trustee. The reporting person disclaims beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein."}],"balance_after":243885,"source":{"system":"sec-edgar","filing":"0001214659-21-006497","document":"marketforms-53110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465921006497/marketforms-53110.xml","form_type":"4"}},{"id":2671593,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-11T21:43:06.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":16498,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":743885,"source":{"system":"sec-edgar","filing":"0001214659-21-006497","document":"marketforms-53110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465921006497/marketforms-53110.xml","form_type":"4"}},{"id":2679035,"issuer":{"id":9606,"kind":"organization","name":"Latch, Inc.","symbol":"LTCH"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class B common stock","published_at":"2021-06-07T22:39:56.000Z","date":"2021-06-04","kind":"exercise","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-249640), the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination (the \"Business Combination\"), on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On June 4, 2021, TS Innovation Acquisitions Corp. (\"TSIA\" and the former name of the Issuer) consummated the Business Combination with Latch, Inc.  In connection with the Business Combination, each Class B share converted to one Class A share.  The reporting person resigned as a director of the Issuer upon consummation of the Business Combination."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 4, 2021, TS Innovation Acquisitions Corp. (\"TSIA\" and the former name of the Issuer) consummated the Business Combination with Latch, Inc.  In connection with the Business Combination, each Class B share converted to one Class A share.  The reporting person resigned as a director of the Issuer upon consummation of the Business Combination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-249640), the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination (the \"Business Combination\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 4, 2021, TS Innovation Acquisitions Corp. (\"TSIA\" and the former name of the Issuer) consummated the Business Combination with Latch, Inc.  In connection with the Business Combination, each Class B share converted to one Class A share.  The reporting person resigned as a director of the Issuer upon consummation of the Business Combination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-249640), the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination (the \"Business Combination\"), on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-249640), the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination (the \"Business Combination\"), on a one-for-one basis."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-249640), the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination (the \"Business Combination\"), on a one-for-one basis."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On June 4, 2021, TS Innovation Acquisitions Corp. (\"TSIA\" and the former name of the Issuer) consummated the Business Combination with Latch, Inc.  In connection with the Business Combination, each Class B share converted to one Class A share.  The reporting person resigned as a director of the Issuer upon consummation of the Business Combination."}],"balance_after":0,"derivative":{"underlying":"Class A common stock"},"source":{"system":"sec-edgar","filing":"0000899243-21-022358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000089924321022358/doc4.xml","form_type":"4"}},{"id":2679034,"issuer":{"id":9606,"kind":"organization","name":"Latch, Inc.","symbol":"LTCH"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class A Common Stock","published_at":"2021-06-07T22:39:56.000Z","date":"2021-06-04","kind":"exercise","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 4, 2021, TS Innovation Acquisitions Corp. (\"TSIA\" and the former name of the Issuer) consummated the Business Combination with Latch, Inc.  In connection with the Business Combination, each Class B share converted to one Class A share.  The reporting person resigned as a director of the Issuer upon consummation of the Business Combination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-249640), the shares of Class B common stock, par value $0.0001 per share, will automatically convert into shares of Class A common stock, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination (the \"Business Combination\"), on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 4, 2021, TS Innovation Acquisitions Corp. (\"TSIA\" and the former name of the Issuer) consummated the Business Combination with Latch, Inc.  In connection with the Business Combination, each Class B share converted to one Class A share.  The reporting person resigned as a director of the Issuer upon consummation of the Business Combination."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000899243-21-022358","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000089924321022358/doc4.xml","form_type":"4"}},{"id":2858649,"issuer":{"id":140810,"kind":"organization","name":"Tishman Speyer Innovation Corp. II","symbol":"TSIB"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Redeemable warrants","published_at":"2021-02-16T23:03:14.000Z","date":"2021-02-12","kind":"purchase","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person purchased 25,000 units of Tishman Speyer Innovation Corp. II (the \"Issuer\") for $10.00 per unit directly from the underwriters in connection with the Issuer's initial public offering for an aggregate purchase price of $250,000. Each unit consists of one of the issuer's Class A common stock, par value $0.0001 per share, and one-fifth of one redeemable warrant."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share.\nThe warrants will become exercisable on the later of 30 days after the completion of the Issuer's initial business combination and 12 months from the closing of the Issuer's initial public offering.\nThe warrants will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation, as described under the heading \"Description of Securities-Redeemable Warrants-Public Stockholders' Warrants\" in the Issuer's registration statement on Form S-1 (File No. 333-252423)."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person purchased 25,000 units of Tishman Speyer Innovation Corp. II (the \"Issuer\") for $10.00 per unit directly from the underwriters in connection with the Issuer's initial public offering for an aggregate purchase price of $250,000. Each unit consists of one of the issuer's Class A common stock, par value $0.0001 per share, and one-fifth of one redeemable warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person purchased 25,000 units of Tishman Speyer Innovation Corp. II (the \"Issuer\") for $10.00 per unit directly from the underwriters in connection with the Issuer's initial public offering for an aggregate purchase price of $250,000. Each unit consists of one of the issuer's Class A common stock, par value $0.0001 per share, and one-fifth of one redeemable warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share.\nThe warrants will become exercisable on the later of 30 days after the completion of the Issuer's initial business combination and 12 months from the closing of the Issuer's initial public offering.\nThe warrants will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation, as described under the heading \"Description of Securities-Redeemable Warrants-Public Stockholders' Warrants\" in the Issuer's registration statement on Form S-1 (File No. 333-252423)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share.\nThe warrants will become exercisable on the later of 30 days after the completion of the Issuer's initial business combination and 12 months from the closing of the Issuer's initial public offering.\nThe warrants will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation, as described under the heading \"Description of Securities-Redeemable Warrants-Public Stockholders' Warrants\" in the Issuer's registration statement on Form S-1 (File No. 333-252423)."}],"balance_after":5000,"derivative":{"underlying":"Class A common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-010912","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919121010912/doc4.xml","form_type":"4"}},{"id":2858648,"issuer":{"id":140810,"kind":"organization","name":"Tishman Speyer Innovation Corp. II","symbol":"TSIB"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A common stock","published_at":"2021-02-16T23:03:14.000Z","date":"2021-02-12","kind":"purchase","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person purchased 25,000 units of Tishman Speyer Innovation Corp. II (the \"Issuer\") for $10.00 per unit directly from the underwriters in connection with the Issuer's initial public offering for an aggregate purchase price of $250,000. Each unit consists of one of the issuer's Class A common stock, par value $0.0001 per share, and one-fifth of one redeemable warrant."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person purchased 25,000 units of Tishman Speyer Innovation Corp. II (the \"Issuer\") for $10.00 per unit directly from the underwriters in connection with the Issuer's initial public offering for an aggregate purchase price of $250,000. Each unit consists of one of the issuer's Class A common stock, par value $0.0001 per share, and one-fifth of one redeemable warrant."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reporting person purchased 25,000 units of Tishman Speyer Innovation Corp. II (the \"Issuer\") for $10.00 per unit directly from the underwriters in connection with the Issuer's initial public offering for an aggregate purchase price of $250,000. Each unit consists of one of the issuer's Class A common stock, par value $0.0001 per share, and one-fifth of one redeemable warrant."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-21-010912","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919121010912/doc4.xml","form_type":"4"}},{"id":2881196,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-03T21:22:48.000Z","date":"2020-10-21","kind":"gift","acquired":false,"shares":305918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On October 21, 2020, the reporting person transferred 305,918 shares of common stock to an irrevocable grantor trust having an independent trustee. The reporting person disclaims beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein."}],"balance_after":727387,"source":{"system":"sec-edgar","filing":"0001214659-21-001199","document":"marketforms-51228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465921001199/marketforms-51228.xml","form_type":"5"}},{"id":3005026,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-10-16T19:47:54.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":65228,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"68,815 of the shares are held jointly with spouse."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":68815},"source":{"system":"sec-edgar","filing":"0001209191-20-055040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919120055040/doc4.xml","form_type":"4"}},{"id":3005025,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-10-16T19:47:54.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":22328,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23556},"source":{"system":"sec-edgar","filing":"0001209191-20-055040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919120055040/doc4.xml","form_type":"4"}},{"id":3005024,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T19:47:54.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":68815,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"68,815 of the shares are held jointly with spouse."}],"balance_after":94481,"source":{"system":"sec-edgar","filing":"0001209191-20-055040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919120055040/doc4.xml","form_type":"4"}},{"id":3005023,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T19:47:54.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":23556,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock and Series A Preferred Stock (the \"Preferred Stock\") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."}],"balance_after":25666,"source":{"system":"sec-edgar","filing":"0001209191-20-055040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919120055040/doc4.xml","form_type":"4"}},{"id":3116020,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-09T20:04:37.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":9969,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1033305,"source":{"system":"sec-edgar","filing":"0001214659-20-005494","document":"marketforms-49012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465920005494/marketforms-49012.xml","form_type":"4"}},{"id":3168229,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-28T20:33:28.000Z","date":"2020-04-24","kind":"other","acquired":true,"shares":8039,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":1023336,"source":{"system":"sec-edgar","filing":"0001214659-20-003820","document":"marketforms-48642.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465920003820/marketforms-48642.xml","form_type":"4"}},{"id":3215444,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T20:39:43.000Z","date":"2020-03-04","kind":"other","acquired":true,"shares":8217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":1015297,"source":{"system":"sec-edgar","filing":"0001214659-20-002530","document":"marketforms-48289.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465920002530/marketforms-48289.xml","form_type":"4"}},{"id":3328794,"issuer":{"id":127463,"kind":"organization","name":"DraftKings Holdings Inc.","symbol":"DKNG"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Common Stock","published_at":"2019-12-31T23:38:18.000Z","date":"2019-12-31","kind":"other","acquired":true,"shares":20000,"price":0.0001,"value":2.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On December 31, 2019, Eagle Equity Partners, LLC, the sponsor of the Issuer (the \"Sponsor\"), transferred 20,000 shares of Class B common stock of the Issuer to each of the Issuer's independent directors at a price per share equal to par value.  The Reporting Person is an independent director of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 31, 2019, Eagle Equity Partners, LLC, the sponsor of the Issuer (the \"Sponsor\"), transferred 20,000 shares of Class B common stock of the Issuer to each of the Issuer's independent directors at a price per share equal to par value.  The Reporting Person is an independent director of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading \"Description of Securities\" in the Issuer's Registration Statement on Form S-1 (File No. 333-230815) (the \"Registration Statement\") and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading \"Description of Securities\" in the Issuer's Registration Statement on Form S-1 (File No. 333-230815) (the \"Registration Statement\") and have no expiration date."}],"balance_after":20000,"derivative":{"underlying":"Class A Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-19-077399","document":"tm1928450d4_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000110465919077399/tm1928450d4_4.xml","form_type":"4"}},{"id":3362820,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-21T21:43:52.000Z","date":"2019-11-11","kind":"gift","acquired":false,"shares":446623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On November 11, 2019, the reporting person transferred 446,623 shares of common stock to an irrevocable grantor trust having an independent trustee. The reporting person disclaims beneficial ownership of these shares except to the extent, if any, of the reporting person's pecuniary interest therein."}],"balance_after":1007080,"source":{"system":"sec-edgar","filing":"0001214659-19-007335","document":"marketforms-46384.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465919007335/marketforms-46384.xml","form_type":"4"}},{"id":3362819,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-21T21:43:52.000Z","date":"2019-11-19","kind":"other","acquired":true,"shares":8217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":1453703,"source":{"system":"sec-edgar","filing":"0001214659-19-007335","document":"marketforms-46384.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465919007335/marketforms-46384.xml","form_type":"4"}},{"id":3386168,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-30T00:07:23.000Z","date":"2019-10-25","kind":"other","acquired":true,"shares":8217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":1445486,"source":{"system":"sec-edgar","filing":"0001214659-19-006702","document":"marketforms-45998.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465919006702/marketforms-45998.xml","form_type":"4"}},{"id":3406216,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-25T22:24:33.000Z","date":"2019-09-23","kind":"other","acquired":true,"shares":8217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":1437269,"source":{"system":"sec-edgar","filing":"0001214659-19-006019","document":"marketforms-45835.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465919006019/marketforms-45835.xml","form_type":"4"}},{"id":3419378,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-09-09T22:02:03.000Z","date":"2019-09-05","kind":"other","acquired":true,"shares":8217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":1429052,"source":{"system":"sec-edgar","filing":"0001214659-19-005740","document":"marketforms-45711.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000121465919005740/marketforms-45711.xml","form_type":"4"}},{"id":3457877,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-22T20:26:55.000Z","date":"2019-07-18","kind":"other","acquired":true,"shares":8217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":1420835,"source":{"system":"sec-edgar","filing":"0001209191-19-042877","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919119042877/doc4.xml","form_type":"4"}},{"id":3462408,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-12T21:11:30.000Z","date":"2019-07-10","kind":"other","acquired":true,"shares":5590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution of shares of the Issuer's common stock from VVAG LLC to its members."}],"balance_after":1412618,"source":{"system":"sec-edgar","filing":"0001209191-19-041957","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919119041957/doc4.xml","form_type":"4"}},{"id":3479893,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-25T00:02:34.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":16377,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1407028,"source":{"system":"sec-edgar","filing":"0001209191-19-038866","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919119038866/doc4.xml","form_type":"4"}},{"id":3611367,"issuer":{"id":4584,"kind":"organization","name":"Target Hospitality Corp.","symbol":"TH"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2019-03-05T22:42:45.000Z","date":"2019-03-05","kind":"purchase","acquired":true,"shares":5000,"price":10.2,"value":51000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.185 to $10.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001144204-19-012302","document":"tv515522_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000114420419012302/tv515522_4.xml","form_type":"4"}},{"id":3622939,"issuer":{"id":4584,"kind":"organization","name":"Target Hospitality Corp.","symbol":"TH"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2019-03-02T00:21:39.000Z","date":"2019-03-01","kind":"purchase","acquired":true,"shares":5000,"price":10.13,"value":50650.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001144204-19-011740","document":"tv515257_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000114420419011740/tv515257_4.xml","form_type":"4"}},{"id":3690526,"issuer":{"id":4584,"kind":"organization","name":"Target Hospitality Corp.","symbol":"TH"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2019-01-22T22:53:18.000Z","date":"2019-01-22","kind":"purchase","acquired":true,"shares":20000,"price":0.0031,"value":62.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Class B Ordinary Shares are convertible for the Issuer's Class A Ordinary Shares as described under the heading \"Description of Securities-Founder Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-222279) and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Class B Ordinary Shares are convertible for the Issuer's Class A Ordinary Shares as described under the heading \"Description of Securities-Founder Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-222279) and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Class B Ordinary Shares are convertible for the Issuer's Class A Ordinary Shares as described under the heading \"Description of Securities-Founder Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-222279) and have no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Class B Ordinary Shares are convertible for the Issuer's Class A Ordinary Shares as described under the heading \"Description of Securities-Founder Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-222279) and have no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Class B Ordinary Shares are convertible for the Issuer's Class A Ordinary Shares as described under the heading \"Description of Securities-Founder Shares\" in the Issuer's registration statement on Form S-1 (File No. 333-222279) and have no expiration date."}],"balance_after":20000,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001144204-19-002314","document":"tv511341_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000114420419002314/tv511341_form4.xml","form_type":"4"}},{"id":3788056,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2018-10-17T21:31:19.000Z","date":"2018-10-15","kind":"exercise","acquired":false,"shares":3565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":18716},"source":{"system":"sec-edgar","filing":"0001209191-18-055379","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919118055379/doc4.xml","form_type":"4"}},{"id":3788055,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-17T21:31:19.000Z","date":"2018-10-15","kind":"exercise","acquired":true,"shares":18716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date."}],"balance_after":1390651,"source":{"system":"sec-edgar","filing":"0001209191-18-055379","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919118055379/doc4.xml","form_type":"4"}},{"id":4059522,"issuer":{"id":5337,"kind":"organization","name":"CAPRICOR THERAPEUTICS, INC."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-14T22:16:59.000Z","date":"2017-12-27","kind":"gift","acquired":false,"shares":17786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift by the Reporting Person for estate planning purposes to an irrevocable blind grantor trust, which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust."}],"balance_after":19298,"source":{"system":"sec-edgar","filing":"0001144204-18-009043","document":"tv485800_5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133869/000114420418009043/tv485800_5.xml","form_type":"5"}},{"id":4059521,"issuer":{"id":5337,"kind":"organization","name":"CAPRICOR THERAPEUTICS, INC."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-14T22:16:59.000Z","date":"2017-12-26","kind":"gift","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift by the Reporting Person for estate planning purposes to an irrevocable blind grantor trust, which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust."}],"balance_after":37084,"source":{"system":"sec-edgar","filing":"0001144204-18-009043","document":"tv485800_5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133869/000114420418009043/tv485800_5.xml","form_type":"5"}},{"id":4095946,"issuer":{"id":4584,"kind":"organization","name":"Target Hospitality Corp.","symbol":"TH"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Private Placement Warrants","published_at":"2018-01-19T00:10:05.000Z","date":"2018-01-17","kind":"grant","acquired":true,"shares":333334,"price":1.5,"value":500001.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Private Placement Warrant (\"PPW\") is exercisable to purchase one Class A ordinary share at $11.50 per share, subject to adjustment as described under the headings \"Description of Securities-Warrants-Private Placement Warrants\" and \"Description of Securities-Warrants-Private Placement Warrants\" in the Issuer's registration statement on Form S-1 (File No. 333-222279)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The PPWs become exercisable beginning on the later of January 17, 2019 or 30 days after the completion of the Issuer's initial business combination as described under the headings \"Description of Securities-Warrants-Private Placement Warrants\" and \"Description of Securities-Warrants-Private Placement Warrants\" in the Issuer's registration statement on Form S-1 (File No. 333-222279)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PPWs will expire five years after the completion of the Issuer's initial business combination or earlier upon redemption or liquidation as described under the headings \"Description of Securities--Warrants-Private Placement Warrants\" and \"Description of Securities--Warrants-Private Placement Warrants\" in the Issuer's registration statement on Form S-1 (File No. 333-222279)."}],"balance_after":333334,"derivative":{"exercise_price":11.5,"underlying":"Class A Ordinary Shares","underlying_shares":333334},"source":{"system":"sec-edgar","filing":"0001144204-18-002700","document":"tv483606_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000114420418002700/tv483606_form4.xml","form_type":"4"}},{"id":4107970,"issuer":{"id":5337,"kind":"organization","name":"CAPRICOR THERAPEUTICS, INC."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-04T22:03:06.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"10,500 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 7,500 shares will vest 1/12 on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting."}],"balance_after":18000,"derivative":{"exercise_price":1.57,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001144204-18-000861","document":"tv482718_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133869/000114420418000861/tv482718_4.xml","form_type":"4"}},{"id":4190883,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-06T00:25:02.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":8810,"price":88.79,"value":782239.9,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F3","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option provided for vesting in 12 equal monthly installments following June 20, 2017."}],"balance_after":0,"derivative":{"exercise_price":91.21,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":8810},"source":{"system":"sec-edgar","filing":"0001209191-17-056236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117056236/doc4.xml","form_type":"4"}},{"id":4190882,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-06T00:25:02.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":7000,"price":129.13,"value":903910.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F3","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option provided for vesting in 12 equal monthly installments following June 1, 2016."}],"balance_after":0,"derivative":{"exercise_price":50.87,"expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001209191-17-056236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117056236/doc4.xml","form_type":"4"}},{"id":4190881,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-06T00:25:02.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":120.77,"value":1207700.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F3","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option provided for vesting in 12 equal monthly installments following June 9, 2015."}],"balance_after":0,"derivative":{"exercise_price":59.23,"expiration_date":"2025-06-08","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-17-056236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117056236/doc4.xml","form_type":"4"}},{"id":4190880,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-10-06T00:25:02.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":178.65,"value":8932500.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F3","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration less the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option provided for vesting of 1/36th of the shares subject thereto on February 28, 2014, and for vesting of the remaining shares subject thereto in 35 equal monthly installments commencing March 30, 2014."}],"balance_after":0,"derivative":{"exercise_price":1.35,"expiration_date":"2024-03-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-056236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117056236/doc4.xml","form_type":"4"}},{"id":4190879,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-06T00:25:02.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":1807,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F3","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units, held by a non-employee director of the Company (each a \"Director Restricted Stock Unit\").  Pursuant to the terms of the Merger Agreement, each Director Restricted Stock Unit held by the Reporting Person fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of (A) $180.00, multiplied by (B) the total number of shares of Company common stock subject to such Director Restricted Stock Unit."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117056236/doc4.xml","form_type":"4"}},{"id":4190878,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-06T00:25:02.000Z","date":"2017-10-03","kind":"other","acquired":false,"shares":2553,"price":180,"value":459540.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F3","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."}],"balance_after":1807,"source":{"system":"sec-edgar","filing":"0001209191-17-056236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117056236/doc4.xml","form_type":"4"}},{"id":4190877,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-06T00:25:02.000Z","date":"2017-10-03","kind":"disposition_to_issuer","acquired":false,"shares":70050,"price":180,"value":12609000.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Gilead Sciences, Inc., a Delaware corporation (\"Parent\"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Company common stock held by the Reporting Person, other than the shares described in Note 3 below, was validly tendered for $180.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"date","element":"transactionDate","label":"F3","text":"On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Parent (the \"Merger\"), and, pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $180.00 (the \"per-share merger consideration\"), without interest and subject to any required withholding of taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-056236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117056236/doc4.xml","form_type":"4"}},{"id":4190876,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-06T00:25:02.000Z","date":"2017-09-28","kind":"other","acquired":true,"shares":70050,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were transferred from an irrevocable blind grantor trust, which is managed by an independent trustee, for no consideration. The Reporting Person holds no voting or dispositive power over the securities held by the trust."}],"balance_after":70050,"source":{"system":"sec-edgar","filing":"0001209191-17-056236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117056236/doc4.xml","form_type":"4"}},{"id":4274384,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-06-22T18:38:21.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":8810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest in 12 successive equal monthly installments following the date of grant."}],"balance_after":8810,"derivative":{"exercise_price":91.21,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":8810},"source":{"system":"sec-edgar","filing":"0001209191-17-041305","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117041305/doc4.xml","form_type":"4"}},{"id":4274383,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-22T18:38:21.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":2410,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4360,"source":{"system":"sec-edgar","filing":"0001209191-17-041305","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117041305/doc4.xml","form_type":"4"}},{"id":4448388,"issuer":{"id":172664,"kind":"organization","name":"Kite Pharma, Inc.","symbol":"KITE"},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-14T23:17:16.000Z","date":"2016-09-28","kind":"gift","acquired":false,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Gift by the Reporting Person for estate planning purposes to an irrevocable blind grantor trust, which is managed by an independent trustee. The Reporting Person holds no voting or dispositive power over the securities held by the trust."}],"balance_after":1950,"source":{"system":"sec-edgar","filing":"0001209191-17-010786","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000120919117010786/doc5.xml","form_type":"5"}},{"id":4503381,"issuer":{"id":5337,"kind":"organization","name":"CAPRICOR THERAPEUTICS, INC."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-01-05T02:44:18.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":16060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"8,560 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 7,500 shares will vest 1/12 on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting."}],"balance_after":16060,"derivative":{"exercise_price":2.55,"exercise_date":"2017-01-03","expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":16060},"source":{"system":"sec-edgar","filing":"0001144204-17-000704","document":"v456180_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133869/000114420417000704/v456180_4.xml","form_type":"4"}}]}